glp-1 news today 2025 november 5 Eli Lilly to seek approval of new weight-loss drug this year Novo Nordisk, Lilly strike deal

This minor yet impactful alteration improves enzymatic resistance, helping the molecule remain intact in research conditions that simulate complex biological environments

Thats when I started building a collection of slow cooker GLP-1 friendly meals that actually solve this problem

So far only one oral GLP-1 has appeared on the market, in 2019

These agents include: Tirzepatide (Mounjaro, Zepbound though technically a dual GIP/GLP-1 receptor agonist) Semaglutide (Ozempic, Wegovy, Rybelsus) Liraglutide (Victoza, Saxenda) Dulaglutide (Trulicity) Exenatide (Byetta, Bydureon) They are widely used in both endocrinology and obesity medicine for managing diabetes, weight, and cardiovascular risk

The first-time AOM semaglutide prescribing rate was 0.1% in January 2024 and reached 0.2% by July 2024